BioCentury
ARTICLE | Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

October 12, 2018 12:15 PM UTC

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo. The compound is an oral Bruton's tyrosine kinase (Btk) inhibitor that Merck discovered in-house. Data were presented at the European Committee for Treatment and Research in Multiple Sclerosis meeting in Berlin.

Merck reported in March that evobrutinib met the primary endpoints in the trial of reducing the total number of gadolinium-enhancing T1 lesions from baseline to weeks 12, 16, 20 and 24 vs. placebo, but did not disclose details (see "Merck's Evobrutinib Meets in Phase IIb for MS")...

BCIQ Company Profiles

Biogen Inc.

Merck KGaA

BCIQ Target Profiles

Bruton's tyrosine kinase (Btk)